00:00It's Benzinga bringing Wall Street to Main Street.
00:02Novo Nordisk raised its 2026 guidance after strong early performance from its WEGA-V weight loss pill
00:09while reporting mixed first quarter results according to CNBC. Sales rose 32% to $15.2
00:17billion and operating profit increased 65% while adjusted sales fell 4% and adjusted profit
00:25declined 6% due to a $4.2 billion provision reversal.
00:31WEGA-V pill sales reached 2.26 billion kroner, exceeding estimates of 1.16 billion kroner
00:37with about 1.3 million prescriptions in the quarter. Injectable WEGA-V sales rose 12% to
00:4418.2 billion kroner while Ozempic sales fell 8% but topped expectations. The company expects
00:51adjusted sales and profit to decline 4% to 12%, narrowing prior guidance of 5% to 13%.
00:57For all things money, visit Benzinga.com.
Comments